Robo Medical Completes a New Financing Round of Tens of Millions of Yuan, with MedBio Capital Continuing to Serve as Exclusive Financial Advisor

2025-07-18 08:01:00

Robo Medical Completes a New Financing Round of Tens of Millions of Yuan, with MedBio Capital Continuing to Serve as Exclusive Financial Advisor, cover image

Shenzhen Robo Medical Technology Co., Ltd. (hereinafter “Robo Medical”) has recently completed a strategic financing round of tens of millions of yuan.

The round was led by Yuanchang Fund under Fenglei Capital (丰雷资本旗下元畅基金), with existing shareholder Taikun Fund (泰鲲基金) participating as a follow-on investor, and MedBio Capital continued to serve as exclusive financial advisor.

Proceeds from this round will be used primarily to accelerate R&D iteration of the intelligent surgical robot product matrix, global market expansion and the recruitment of top talent, marking a key step for the company on the path of localizing high-end medical equipment.

Exterior signage on the Robo Medical office building

The success of this financing for Robo Medical demonstrates the capital market’s firm confidence in original, innovative high-end equipment from China.

Surgical robots are an important setting for the application of medical AI. The Robo team has not only overcome the core technical bottleneck of operating a small-diameter continuum flexible arm, but has also built a complete product ecosystem, which is a key reason for the support from capital.

It is reported that this financing will be used mainly in three ways: iteration of core technologies and expansion of the product line, accelerating performance optimization and clinical adoption of the existing core product, the EndoFaster (速易必) surgical robot, while advancing R&D of the next-generation “EndoDreams” surgical robot; capacity expansion and supply-chain optimization, as the technological revolution that typifies the new era is rebuilding new forms of the global economy, and entire industry chains related to new technologies—including production, storage, transportation and sales—are being rebuilt under the influence of new scientific and technological advances; deeper clinical promotion, expanding clinical research collaborations with leading hospitals and accelerating market validation and adoption of the products.

Clinical demonstration of Robo Medical’s gastrointestinal endoscopic surgical robot

As a globally leading China-developed solution, the gastrointestinal endoscopic surgical robot EndoFaster, independently developed by Robo Medical, has three major advantages:

A break from the conventional approach: from “one-handed blind dissection” to “bimanual visualization.”

The lead surgeon operates the endoscopic knife while EndoFaster’s robotic arm simultaneously retracts tissue, leaving no blind spots such as the gastric fundus and cardia;

Much greater efficiency: procedure time cut in half.

In comparative animal studies, ESD assisted by EndoFaster required only 18.8 minutes (versus 32.8 minutes with the conventional approach), while the muscle injury rate declined substantially.

The learning period for novice physicians is shortened by 60%, enabling them to perform the procedure independently in a shorter time.

Illustration of experimental research on EndoFaster robot-assisted ESD

Illustration of research on the ESD learning curve with the EndoFaster system

Non-invasive expansion: early cancer treatment.

Traction with the flexible arm exposes the lesion, with 4-degree-of-freedom master-slave control and sub-millimeter operational precision.

Illustration of a case of early gastric-angle cancer using EndoFaster traction

Robo Medical’s story began with a simple and firm conviction: to bring more precise, safer and more widely accessible medical technology to more lives.

A group of scientists and engineers with a shared ideal, deeply engaged in medical devices and robotics, came together.

They knew well that the combination of “robotics + medicine” is not only a technological breakthrough, but also an expression of care for both physicians and patients.

Robo Medical thus came into being, resolved to “empower healthcare with technology and make medicine borderless.”

It is understood that Robo Medical’s future plans will focus on three directions: from the gastrointestinal tract to coverage of multiple departments, as the company will, based on its second-generation dual-channel flexible robotic arm system EndoDreams, expand its products into new fields such as urology and gynecology; from tertiary hospitals to primary-level hospitals, as the equipment will, by virtue of its low-cost advantage, be accelerated into the national market to help implement the national public health program of “early diagnosis and early treatment of gastrointestinal cancer”; and from China to the world, as the company will be based in China and deeply cultivate the Chinese market, while steadily advancing registration and market development in key countries in Asia, Latin America and Eastern Europe, setting a new paradigm for Chinese high-end medical equipment going global.

MedBio Capital said that the incidence of gastrointestinal disease remains high, and the prevention and treatment of early-stage cancers of the gastrointestinal system is of paramount importance.

Robo Medical has been deeply engaged in natural-orifice surgical robotics. After more than 10 years of original technological accumulation and development, it has developed the internationally leading EndoFaster and EndoDreams surgical robot systems, and is committed to building the next-generation gastrointestinal endoscopic surgery platform.

Congratulations to the Robo Medical team and to new and existing shareholders. We firmly believe that original Chinese medical devices such as those of Robo Medical will bring clinical benefits to a broader range of physicians and patients, and we will continue to accompany the company in its development.

About MedBio Capital

MedBio Capital is a boutique investment bank focused on life sciences and healthcare, committed to serving as a capital and strategic partner to leading scientists and entrepreneurs. Its core team has worked in the healthcare industry for many years, covering key stages in R&D, clinical development and the market, and brings combined experience in investment, investment banking and consulting. Team members have collectively completed more than RMB 10 billion in financing transactions and have served more than a dozen leading listed healthcare companies.

This article was adapted from the MedBio Capital WeChat official account.